Top Tech Companies (764)
Don't see your company?
Create a company profile
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA™ (Trilaciclib). G1 has a deep clinical pipeline evaluating targeted cancer therapies in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers, and is also advancing rintodestrant, a potential best-in-class oral selective estrogen receptor degrader, or SERD, for the treatment of ER+ breast cancer. In 2020, G1 out-licensed global development and commercialization rights to its differentiated oral CDK4/6 inhibitor, lerociclib. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics. View our social community guidelines here: https://www.g1therapeutics.com/social-guidelines
At Merz Therapeutics, we seek to address the unique needs of people who suffer from movement disorders, neurological conditions, and other health conditions that severely impact patients’ quality of life. With our patient-centric approach, cutting-edge research and development efforts, highly-scientific medical affairs resources and dedicated commercial teams, we continue the advancement of new and individualized treatment standards, including botulinum toxin. Merz Therapeutics is headquartered in Frankfurt am Main, Germany and is represented in more than 90 countries, with a North America affiliate based in Raleigh, North Carolina. Merz Therapeutics GmbH is part of the Merz Group, a privately held, family-owned company that has dedicated more than 110 years to developing innovations that serve unmet patient and customer needs.
CyDex Pharmaceuticals is a pharmaceutical company that engages in the development and commercialization of drugs specifically designed.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases. Mirum’s approved medication is LIVMARLI® (maralixibat) oral solution which is approved in the U.S. for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older. Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults. Maralixibat (LIVMARLI), an oral ileal bile acid transporter (IBAT) inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the MARCH Phase 3 study for progressive familial intrahepatic cholestasis (PFIC) and the EMBARK Phase 2b study for patients with biliary atresia. In addition, Mirum has an expanded access program open in Canada, Australia, the UK and several countries in Europe for eligible patients with Alagille syndrome. Mirum has submitted a Marketing Authorization Application to the European Medicines Agency for maralixibat for the treatment of cholestatic liver disease in patients with Alagille syndrome. Mirum’s second investigational treatment, volixibat, also an oral IBAT inhibitor, is being evaluated in three potentially registrational studies including the OHANA Phase 2b study for pregnant women with intrahepatic cholestasis of pregnancy, VISTAS Phase 2b study for adults with primary sclerosing cholangitis, and the VANTAGE Phase 2b study for primary biliary cholangitis.
Prinston Pharmaceutical, Inc. is a fully integrated pharmaceutical company engaged in product development, product registration, manufacturing, marketing, and sales of high quality affordable generic prescription products to customers. We deliver and maintain high quality and integrity in all our products, which are manufactured in world-class cGMP manufacturing facilities.
Colorcon® is a world leader in the development, supply and technical support of formulated film coating systems, modified release technologies, and functional excipients for the pharmaceutical and nutritional industries. Our best-in-class products and technologies are complemented by our extensive formulation experience, application data and value-added services to support all phases of solid oral dose design, development and manufacture. Our focus on market issues and technology development has earned Colorcon an international reputation as a pharmaceutical supplier of choice. That reputation is based on superior product quality, unparalleled technical support, extensive regulatory assistance and reliable supply from multiple locations. Colorcon has 22 technical service laboratories globally and more than 1300 employees exclusively dedicated to its customer base. Follow us on Twitter @Colorcon
QuVa Pharma is a leader in 503B outsourced compounding, serving all 50 states with a full portfolio of sterile, ready-to-administer injectable products. QuVa was purpose-built to change the 503B industry for the better and is leading the way in making it more safe, efficient, and reliable. With unmatched expertise in cGMPs and sterile pharmaceutical manufacturing, we achieve higher than required quality and safety standards and maintain a leading FDA compliance record, so hospitals can more confidently and reliably focus on patient care. While our leading cGMP processes, sterile-to-sterile portfolio, and expansive capacity of 300,000 sq ft across four facilities are the foundation of success, it is our transparency, customer-focused service, and contracted supply arrangements that enable us to help hospitals and health systems better meet their patient care and operational needs. As FDA compliance becomes more stringent, QuVa's ability to reliably supply the highest-quality products is more valuable than ever and allows hospitals to spend more time on patient care and less time worried about beyond use dates, waste, workload inefficiencies, and compliance. That is why QuVa is proud to be recognized as the partner of choice for many of the nation’s leading health systems. So, whether you are calling for a response or being called on for a solution, know that QuVa is accountable, and in us, you always have an answer.
A Cleveland-based pharmacy focused on improving medication adherence for patients with chronic conditions and on multiple medications
PhenoTech a biotechnology company, engages in the discovery, development, and commercialization of reagents for diagnostic.
A Contract Development and Manufacturing Organization (CDMO) that manufactures protein-therapeutic and viral-therapeutic drug products.
.jpeg)
.png)
We bring together families, healthcare providers, and researchers to improve the quality of life for current and future patients. Our mission is to advance scientific and medical innovation through comprehensive patient-centric clinical research, in collaboration with our sponsors and providers. The Accel Research Sites Network offers leading sponsors, clinical research organizations and healthcare providers the ability to execute multi-phase clinical research studies. With a focus on precision and speed, our facilities are built for flexible, results-focused studies, able to be set up and executed on limited timelines. With decades of experience in the healthcare innovation space, you’ll trust that every study, every patient, every outcome will be meticulously managed - with evidenced based results.
Elemental Machines is helping scientists improve experimental reproducibility and accelerate scientific discovery. With a new suite of connected products that harness the power of cloud-based software, machine learning and distributed sensors, Elemental Machines is giving scientists and researchers an easy, powerful and cost-effective solution fo
Evolution Health Group is a full-service healthcare communications agency which has broad strategic capabilities and consists of 3 main divisions, Evolution Medical Communications (with expertise with respect to delivering P2P engagement strategy from pre-launch to LOE), Maestro360 (with expertise in program execution of meetings, events and conventions), BluLava (with expertise with respect to optimizing the customer engagement experience) and Darwin Academy (dedicated to providing novel, interactive peer to peer education). Evolution has proven success in partnering with pharmaceutical customers to launch new products leveraging market insights to drive critical brand planning decisions and maximize outcomes throughout each product’s life cycle. We value creating strong strategic partnerships with our customers by better understanding their challenges and opportunities through ongoing and evolutionary account management best practices. By adhering to the highest possible ethical standards and industry guidelines along with unparalled dedication to our employees and value-added partners, Evolution will work with our customers to help them evolve in order to deliver maximum physician engagement success in the ever-changing pharmaceutical environment. Evolution's focus on innovation has resulted in our creating novel engagement initiatives and proprietary digital offerings that were custom-made with our pharmaceutical clients in mind. Contact us to learn more!
Chase Therapeutics is an early-stage, product-based specialty pharmaceutical company
Veana Therapeutics is dedicated to developing innovative, safe, cancer fighting medicines Veana’s VIMO technology is based on orally bioavailable anti-cancer agents that selectively attack and destroy the energy powerhouses (mitochondria) of cancer cells in a fashion that subsequently stimulates the immune system. Veana’s VIMO platform of α-TEA salt form-based products can be combined with other forms of immunotherapy to further improve anti-tumor activity.
Nalpropion Pharmaceuticals is a biopharmaceutical company focused on the treatment of weight loss.
We founded Precision Medicine Group in 2012 because we believed there was a transformational opportunity to improve the process of bringing new drugs to market. It involves utilizing technology, data, and human expertise. It is a big challenge that requires diverse talents. Our model involves both nurturing and investing organically and acquiring capabilities that we do not have but critically need. Our core executive team is anchored to this model, building life science services that address fundamental changes in healthcare that are necessary for health and outcomes improvement.
OPIS was founded in 1998 by medical doctors from the Pharma Industry and is a Global clinical CRO with 25 years of experience in a wide range of therapeutic areas. OPIS provides full-service, 360° clinical trial support from study concept creation and protocol development to full project execution, study data handling and up to study closure, analysis, and reporting. We manage Phase I-IV, interventional, non-interventional and medical devices studies on an international level. In addition, OPIS also manages pre- and post-marketing clinical investigations for medical and diagnostic devices, nutraceutical, and food supplement studies. Our qualified, fully trained, and dedicated staff has managed 1470 studies to date. OPIS’s strength lies in its people and its specialized teams who assist clients from A-Z with medical writing, scientific and statistical consultancy for trial design and skilled teams of operational staff that ensure high quality project execution, with global coverage. Our mission is to increase the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system... etc. OPIS is committed to continuous growth and expansion, while currently we have affiliates in 17 countries around the world. For more information, visit www.opisresearch.com
Metro Medical Supply is a pharmaceutical company offering nephrology and oncology solutions.
Frontida BioPharm is a Minority-Owned Contract Development & Manufacturing Organization. We work collaboratively with our clients to bring new and improved products to the pharmaceutical market. By leveraging our team's vast knowledge and experience we are able to improve the success of our client's business and product development efforts. Frontida was launched by founding management team members of Frontage Laboratories. Having 15 years of success in the business Frontage remains a thriving CRO that has become a full service R&D organization located in PA, NJ, and China. With strong record of FDA compliance and quality service to global pharmaceutical and biotechnology companies, the Frontage team easily founded Frontida. While Frontage and Frontida remain affiliates, they are separate business entities.
